Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
antithymocyte globulin + basiliximab
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
A combination immunosuppressive therapy consisting of antithymocyte globulin (ATG) and basiliximab. ATG is a polyclonal antibody preparation that depletes T cells, while basiliximab is a chimeric monoclonal antibody that specifically targets the interleukin-2 receptor alpha chain (CD25) on activated T lymphocytes. This combination is used primarily for induction therapy in organ transplantation, particularly kidney transplantation, to prevent acute rejection. Lower doses of ATG combined with basiliximab have shown effective prevention of rejection with fewer adverse effects compared to standard-dose ATG alone.
- Other names
- ATG + basiliximabATG-basiliximabbasiliximab + ATGbasiliximab-ATG
02
Targets
Beyond the preview
Go deeper on antithymocyte globulin + basiliximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on antithymocyte globulin + basiliximab.